

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of all claims in the application.

Listing of Claims

1 - 87. (Cancelled)

88. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent Fc polypeptide, and wherein numbering is according to the EU index.

89. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein numbering is according to the EU index.

90. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent Fc polypeptide, wherein numbering is according to the EU index.

91. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein numbering is according to the EU index.

92. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

93. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239 and at position 332, wherein numbering is according to the EU index.

94. (New) An antibody or immunoadhesin according to claim 92 or 93 wherein said substitution at position 332 is selected from the group consisting of I332D, I332E, I332N, I332Q, I322T, I332H, I332Y, and I332A.

95. (New) An antibody or immunoadhesin according to claim 92 comprising the amino acid substitutions 239D and 332E.

96. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

97. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

98. (New) An antibody or immunoadhesin according to claim 88 or 89 which is selected from the group consisting of 239E/332E, 239Q/332E, 239E/265G, 239E/265N, 239E/265Q, 239D/332D, 239D/332E, 239D/332N, 239D/332Q, 239E/332D, 239E/332N, 239E/332Q, 239N/332D, 239N/332E, 239N/332N, 239N/332Q, 239Q/332D, 239Q/332N, 239Q/332Q, 239E/264I/332E, 239Q/264I/332E, 239E/264I/330Y/332E, 239E/264I/298A/330Y/332E, 239D/297D/332E, 239E/297D/332E, 239D/265V/297D/332E, 239D/265I/297D/332E, 239D/265L/297D/332E, 239D/265F/297D/332E,

239D/265Y/297D/332E, 239D/265H/297D/332E, 239D/265T/297D/332E, 239N/330Y/332E, 239D/330L/332E, 239N/330L/332E, 264I/298A/332E, 239D/298A/332E, 239N/298A/332E, 239D/264I/332E, 239D/264I/298A/332E, 332E/239D/298A, 239D/330Y/332E and 239D/264I/330L/332E.

99. (New) An antibody or immunoadhesin according to claim 98 which is 239D/332E.

100. (New) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330Y.

101. (New) An antibody or immunoadhesin according to claim 98 which is 239D/332E/330L.

102. (New) An antibody or immunoadhesin according to claim 98 which is 239D/332E/298A.

103. (New) An antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent polypeptide, wherein numbering is according to the EU index.

104. (New) An antibody or immunoadhesin according to claim 103 wherein said FcγR is FcγRIIIa.

105. (New) An antibody or immunoadhesin according to claim 104 wherein said FcγRIIIa is a V158 or F158 allotype of FcγRIIIa.

106. (New) An antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said substitution is 239D.

107. (New) An antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said substitution is 239E.

108. (New) An antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said antibody or immunoadhesin is an antibody.

109. (New) An antibody according to claim 108 wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, a monoclonal antibody and an antibody fragment.

110. (New) An antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said antibody or immunoadhesin further comprises an engineered glycoform.

111. (New) An antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said antibody or immunoadhesin has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFα, MUC18, prostate specific membrane antigen (PSMA) and VEGF.

112. (New) A composition comprising the antibody or immunoadhesin according to any of claims 88-93 and 96-97 further comprising a pharmaceutically acceptable carrier.

113. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent Fc polypeptide, and wherein numbering is according to the EU index.

114. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein numbering is according to the EU index.

115. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent Fc polypeptide, wherein numbering is according to the EU index.

116. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at a position selected from the group consisting of 234, 235, 240, 241, 243, 244, 245, 247, 256, 262, 263, 264, 265, 266, 267, 269, 270, 290, 296, 297, 298, 299, 312, 313, 322, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334 and 339, wherein numbering is according to the EU index.

117. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution at position 332, wherein numbering is according to the EU index.

118. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239 and at position 332, wherein numbering is according to the EU index.

119. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 117 and 118 wherein said substitution at position 332 is selected from the group consisting of I332D, I332E, I332N, I332Q, I322T, I332H, I332Y, and I332A.

120. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 119 comprising the amino acid substitutions 239D and 332E.

121. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution at position 239, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

122. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin further comprises an amino acid substitution selected from the group consisting of 234D, 234E, 234N, 234Q, 234T, 234H, 234Y, 234I, 234V, 234F, 235D, 235S, 235N, 235Q, 235T, 235H, 235Y, 235I, 235V, 235F, 240I, 240A, 240T, 240M, 241W, 241L, 241Y, 241E, 241R, 243W, 243L, 243Y, 243R, 243Q, 244H, 245A, 247V, 247G, 262I, 262A, 262T, 262E, 263I, 263A, 263T, 263M, 264L, 264I, 264W, 264T, 264R, 264F, 264M, 264Y, 264E, 265G, 265N, 265Q, 265Y, 265F, 265V, 265I, 265L, 265H, 265T, 266I, 266A, 266T, 266M, 267Q, 267L, 269H, 269Y, 269F, 269R, 296E, 296Q, 296D, 296N, 296S, 296T, 296L, 296I, 296H, 297S, 297D, 297E, 298H, 299I, 299L, 299A, 299S, 299V, 299H, 299F, 299E, 313F, 325Q, 325L, 325I, 325D, 325E, 325A, 325T, 325V, 325H, 327N, 327L, 328M, 328D, 328E, 328N, 328Q, 328F, 328I, 328V, 328T, 328H, 328A, 329F, 330L, 330Y, 330V, 330I, 330F, 330R, 330H, 332D, 332E, 332N, 332Q, 322T, 332H, 332Y, and 332A, wherein numbering is according to the EU index.

123. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 113 or 114 which is selected from the group consisting of 239E/332E, 239Q/332E, 239E/265G, 239E/265N, 239E/265Q, 239D/332D, 239D/332E, 239D/332N,

239D/332Q, 239E/332D, 239E/332N, 239E/332Q, 239N/332D, 239N/332E, 239N/332N, 239N/332Q, 239Q/332D, 239Q/332N, 239Q/332Q, 239E/264I/332E, 239Q/264I/332E, 239E/264I/330Y/332E, 239E/264I/298A/330Y/332E, 239D/297D/332E, 239E/297D/332E, 239D/265V/297D/332E, 239D/265I/297D/332E, 239D/265L/297D/332E, 239D/265F/297D/332E, 239D/265Y/297D/332E, 239D/265H/297D/332E, 239D/265T/297D/332E, 239N/330Y/332E, 239D/330L/332E, 239N/330L/332E, 264I/298A/332E, 239D/298A/332E, 239N/298A/332E, 239D/264I/332E, 239D/264I/298A/332E, 332E/239D/298A, 239D/330Y/332E and 239D/264I/330L/332E.

124. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E.

125. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/330Y.

126. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/330L.

127. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 123 which is 239D/332E/298A.

128. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin of a parent Fc polypeptide, said antibody or immunoadhesin comprising an amino acid substitution selected from the group consisting of 239D, 239E, 239N, 239Q, 239F, 239T, 239H and 239Y, wherein said antibody or immunoadhesin increases binding affinity to an FcγR as compared to said parent polypeptide, wherein numbering is according to the EU index.

129. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 103 wherein said FcγR is FcγRIIIa.

130. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to claim 104 wherein said FcγRIIIa is a V158 or F158 allotype of FcγRIIIa.

131. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 113-118, 121-122 and 124-127 wherein said antibody or immunoadhesin is an antibody.

132. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody according to claim 131 wherein said antibody is selected from the group consisting of a human antibody, a humanized antibody, a monoclonal antibody and an antibody fragment.

133. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 113-118, 121-122 and 124-127 wherein said antibody or immunoadhesin further comprises an engineered glycoform.

134. (New) A method of treating a mammal in need of said treatment, comprising administering an antibody or immunoadhesin according to any of claims 88-93 and 96-97 wherein said antibody or immunoadhesin has specificity for a target antigen selected from the group consisting of CD19, CD20, CD22, CD30, CD33, CD40, CD40L, CD52, Her2/neu, EGFR, EpCAM, MUC1, GD3, CEA, CA 125, HLA-DR, TNFalpha, MUC18, prostate specific membrane antigen (PMSA) and VEGF.